
Soligenix Receives EU Orphan Drug Designation for Dusquetide in Behçet Disease Treatment
Soligenix Inc. has secured European Union orphan drug designation for dusquetide (SGX945) to treat Behçet Disease, providing market exclusivity and advancing treatment options for this rare autoimmune condition.
Read full story























